Eurolife snaps up Baxter’s form-fill-seal unit in India for undisclosed price

Eurolife Healthcare, a specialty drugmaker based in India, picked up the form-fill-seal infusion products unit of U.S.-based Baxter International for an undisclosed price.

The deal consolidates Eurolife’s position as a major player in the form-fill-sealed segment, BW Businessworld reported. The technology is used in sterile manufacturing of liquid drugs and intravenous fluids.

Under the terms of the acquisition, Eurolife gets the products and technology as well as Baxter’s facilities in India. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It’s expected the sale will be closed by the end of the year.

“Eurolife is totally committed to making significant investments in the acquired facilities, in order to expand capacity to feed our flourishing FFS infusions business both locally and globally,” Sandeep Toshniwal, Eurolife’s CEO, said in a statement.

Eurolife, based in Mumbai, was founded in 2001. With the Baxter agreement under its belt it will have manufacturing facilities in Maharashtra, Tamil Nadu and Uttarakhand. The company currently markets to 22 countries in Asia, the Pacific region and Latin America.

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.